Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.983,549,DB00214,Torasemide
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],1.35,550,DB00214,Torasemide
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.998,551,DB00214,Torasemide
,16094676,Cl(nr),"As expected, the Cl(nr) values were significantly slower in DMIA (0.983 versus 1.35 ml/min/kg) and DMIS (0.998 versus 1.36 ml/min/kg) rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],1.36,552,DB00214,Torasemide
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.164,553,DB00214,Torasemide
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.0846,554,DB00214,Torasemide
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.205,555,DB00214,Torasemide
,16094676,time-averaged renal clearance (Cl(r)),"However, the time-averaged renal clearance (Cl(r)) values of torasemide were significantly faster in DMIA (0.164 versus 0.0846 ml/min/kg) and DMIS (0.205 versus 0.0967 ml/min/kg) rats due to urine flow rate-dependent timed-interval Cl(r) of torasemide in rats.",Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16094676/),[ml] / [kg·min],0.0967,556,DB00214,Torasemide
,16344009,maximum concentrations,"Median maximum concentrations in plasma after a 10mg oral dose during a 24h study interval were located at 1h for torasemide, 1h for M1 and 2h for M5.",Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344009/),h,1,5502,DB00214,Torasemide
,16344009,maximum concentrations,"Median maximum concentrations in plasma after a 10mg oral dose during a 24h study interval were located at 1h for torasemide, 1h for M1 and 2h for M5.",Improved solid-phase extraction and HPLC measurement of torasemide and its important metabolites. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16344009/),h,2,5503,DB00214,Torasemide
,32411731,Tmax,"After rapid absorption (Tmax 0.5-1 h), 61% of the bioavailable torasemide was eliminated unchanged in urine.",Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),h,0.5-1,20904,DB00214,Torasemide
,32411731,diuresis,The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs) to 730 ±120 mL after the first torasemide administration and up to 1150 ± 252 mL after 10 administrations at the highest dose.,Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),[ml] / [d],220,20905,DB00214,Torasemide
,32411731,diuresis,The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs) to 730 ±120 mL after the first torasemide administration and up to 1150 ± 252 mL after 10 administrations at the highest dose.,Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),ml,730,20906,DB00214,Torasemide
,32411731,diuresis,The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs) to 730 ±120 mL after the first torasemide administration and up to 1150 ± 252 mL after 10 administrations at the highest dose.,Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),ml,1150,20907,DB00214,Torasemide
,32411731,net fluid loss,"For a daily target diuresis of 460 mL/dog/day in severe pulmonary oedema (net fluid loss 240 mL/dog/day), a computed dose of 0.26 mg/kg/day (3.5 mg/kg/day furosemide-equivalent) was selected for clinical studies.",Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),[ml] / [d·dog],240,20908,DB00214,Torasemide
,8033492,Absolute bioavailability,Absolute bioavailability was essentially 100%.,The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033492/),%,100,21206,DB00214,Torasemide
,15686118,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"In rats with U-ARF, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) was significantly smaller (6380 versus 4450 microg min/ml) than that in control rats.",Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[min·μg] / [ml],6380,22228,DB00214,Torasemide
,15686118,total area under the plasma concentration-time curve from time zero to time infinity (AUC),"In rats with U-ARF, the total area under the plasma concentration-time curve from time zero to time infinity (AUC) was significantly smaller (6380 versus 4450 microg min/ml) than that in control rats.",Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[min·μg] / [ml],4450,22229,DB00214,Torasemide
,15686118,total body clearance,This was due to significantly faster total body clearance (1.57 versus 2.25 ml/min/kg) in the rats.,Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg·min],1.57,22230,DB00214,Torasemide
,15686118,total body clearance,This was due to significantly faster total body clearance (1.57 versus 2.25 ml/min/kg) in the rats.,Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg·min],2.25,22231,DB00214,Torasemide
,15686118,nonrenal clearance,The faster total body clearance in rats with U-ARF could be due to significantly faster nonrenal clearance (1.51 versus 2.22 ml/min/kg due to faster metabolism) since renal clearance (0.0365 versus 0.00199 ml/min/kg) was significantly slower (due to impaired kidney function) than that in control rats.,Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg·min],1.51,22232,DB00214,Torasemide
,15686118,nonrenal clearance,The faster total body clearance in rats with U-ARF could be due to significantly faster nonrenal clearance (1.51 versus 2.22 ml/min/kg due to faster metabolism) since renal clearance (0.0365 versus 0.00199 ml/min/kg) was significantly slower (due to impaired kidney function) than that in control rats.,Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg·min],2.22,22233,DB00214,Torasemide
,15686118,renal clearance,The faster total body clearance in rats with U-ARF could be due to significantly faster nonrenal clearance (1.51 versus 2.22 ml/min/kg due to faster metabolism) since renal clearance (0.0365 versus 0.00199 ml/min/kg) was significantly slower (due to impaired kidney function) than that in control rats.,Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg·min],0.0365,22234,DB00214,Torasemide
,15686118,renal clearance,The faster total body clearance in rats with U-ARF could be due to significantly faster nonrenal clearance (1.51 versus 2.22 ml/min/kg due to faster metabolism) since renal clearance (0.0365 versus 0.00199 ml/min/kg) was significantly slower (due to impaired kidney function) than that in control rats.,Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg·min],0.00199,22235,DB00214,Torasemide
,15686118,urine output,"The 8-h urine output was significantly smaller in rats with U-ARF (178 versus 22.0 ml/kg), however, the 8-h urinary excretion of sodium, potassium, and chloride were not significantly different between two groups of rats.",Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg],178,22236,DB00214,Torasemide
,15686118,urine output,"The 8-h urine output was significantly smaller in rats with U-ARF (178 versus 22.0 ml/kg), however, the 8-h urinary excretion of sodium, potassium, and chloride were not significantly different between two groups of rats.",Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous torasemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686118/),[ml] / [kg],22.0,22237,DB00214,Torasemide
,11850698,C(max),"Administration of torsemide with a standard high-fat, high-carbohydrate breakfast resulted in a decrease in absorption rate (fed: C(max) 988 plus minus 269 ng ml(minus sign1), T(max) 1.50 plus minus 0.64 h; fasting: C(max) 1466 plus minus 202 ng ml(minus sign1), T(max) 0.89 plus minus 0.37 h) but no change in the extent of absorption (fed: AUC 3424 plus minus 841 h ng ml(minus sign1); fasting: AUC 3357 plus minus 859 h ng ml(minus sign1)) or the amount of drug excreted unchanged (fed: % dose 23.5 plus minus 4.3; fasting: % dose 23.7 plus minus 6.2).",Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850698/),ml·ng,988,26374,DB00214,Torasemide
,11850698,T(max),"Administration of torsemide with a standard high-fat, high-carbohydrate breakfast resulted in a decrease in absorption rate (fed: C(max) 988 plus minus 269 ng ml(minus sign1), T(max) 1.50 plus minus 0.64 h; fasting: C(max) 1466 plus minus 202 ng ml(minus sign1), T(max) 0.89 plus minus 0.37 h) but no change in the extent of absorption (fed: AUC 3424 plus minus 841 h ng ml(minus sign1); fasting: AUC 3357 plus minus 859 h ng ml(minus sign1)) or the amount of drug excreted unchanged (fed: % dose 23.5 plus minus 4.3; fasting: % dose 23.7 plus minus 6.2).",Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850698/),h,1.50,26375,DB00214,Torasemide
,11850698,C(max),"Administration of torsemide with a standard high-fat, high-carbohydrate breakfast resulted in a decrease in absorption rate (fed: C(max) 988 plus minus 269 ng ml(minus sign1), T(max) 1.50 plus minus 0.64 h; fasting: C(max) 1466 plus minus 202 ng ml(minus sign1), T(max) 0.89 plus minus 0.37 h) but no change in the extent of absorption (fed: AUC 3424 plus minus 841 h ng ml(minus sign1); fasting: AUC 3357 plus minus 859 h ng ml(minus sign1)) or the amount of drug excreted unchanged (fed: % dose 23.5 plus minus 4.3; fasting: % dose 23.7 plus minus 6.2).",Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850698/),ml·ng,1466,26376,DB00214,Torasemide
,11850698,T(max),"Administration of torsemide with a standard high-fat, high-carbohydrate breakfast resulted in a decrease in absorption rate (fed: C(max) 988 plus minus 269 ng ml(minus sign1), T(max) 1.50 plus minus 0.64 h; fasting: C(max) 1466 plus minus 202 ng ml(minus sign1), T(max) 0.89 plus minus 0.37 h) but no change in the extent of absorption (fed: AUC 3424 plus minus 841 h ng ml(minus sign1); fasting: AUC 3357 plus minus 859 h ng ml(minus sign1)) or the amount of drug excreted unchanged (fed: % dose 23.5 plus minus 4.3; fasting: % dose 23.7 plus minus 6.2).",Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850698/),h,0.89,26377,DB00214,Torasemide
,11850698,AUC,"Administration of torsemide with a standard high-fat, high-carbohydrate breakfast resulted in a decrease in absorption rate (fed: C(max) 988 plus minus 269 ng ml(minus sign1), T(max) 1.50 plus minus 0.64 h; fasting: C(max) 1466 plus minus 202 ng ml(minus sign1), T(max) 0.89 plus minus 0.37 h) but no change in the extent of absorption (fed: AUC 3424 plus minus 841 h ng ml(minus sign1); fasting: AUC 3357 plus minus 859 h ng ml(minus sign1)) or the amount of drug excreted unchanged (fed: % dose 23.5 plus minus 4.3; fasting: % dose 23.7 plus minus 6.2).",Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850698/),h·ml·ng,3424,26378,DB00214,Torasemide
,11850698,AUC,"Administration of torsemide with a standard high-fat, high-carbohydrate breakfast resulted in a decrease in absorption rate (fed: C(max) 988 plus minus 269 ng ml(minus sign1), T(max) 1.50 plus minus 0.64 h; fasting: C(max) 1466 plus minus 202 ng ml(minus sign1), T(max) 0.89 plus minus 0.37 h) but no change in the extent of absorption (fed: AUC 3424 plus minus 841 h ng ml(minus sign1); fasting: AUC 3357 plus minus 859 h ng ml(minus sign1)) or the amount of drug excreted unchanged (fed: % dose 23.5 plus minus 4.3; fasting: % dose 23.7 plus minus 6.2).",Effect of Food on the Pharmacokinetics and Pharmacodynamics of Torsemide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11850698/),h·ml·ng,3357,26379,DB00214,Torasemide
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],254,28416,DB00214,Torasemide
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],330,28417,DB00214,Torasemide
,17295362,AUC,"After oral administration of warfarin at a dose of 2 mg/kg to male rats with oxolamine at doses of 10 and 50 mg/kg, the AUC values of warfarin were significantly greater than the controls (254 and 330 versus 180 microg h/ml).",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[h·μg] / [ml],180,28418,DB00214,Torasemide
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],1280,28419,DB00214,Torasemide
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],1640,28420,DB00214,Torasemide
,17295362,AUC,"After oral oxolamine at doses of 10 and 50 mg/kg, the AUC of phenytoin was significantly greater (1280 and 1640 versus 938 microg min/ml), however, the AUC values of torasemide and clarithromycin were independent of oxolamine.",Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17295362/),[min·μg] / [ml],938,28421,DB00214,Torasemide
,3370063,availability,"From the results of urinary excretion and plasma AUC, the availability of torasemide from the tablet was 80% to 90%, i.e. nearly complete.",Pharmacokinetics and metabolism of torasemide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370063/),%,80,31216,DB00214,Torasemide
,3370063,availability,"From the results of urinary excretion and plasma AUC, the availability of torasemide from the tablet was 80% to 90%, i.e. nearly complete.",Pharmacokinetics and metabolism of torasemide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370063/),%,90,31217,DB00214,Torasemide
,3370063,elimination half-life,"The time of peak was reached at 1 h, the elimination half-life varied from 3 h to 4 h.",Pharmacokinetics and metabolism of torasemide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370063/),h,3,31218,DB00214,Torasemide
,3370063,elimination half-life,"The time of peak was reached at 1 h, the elimination half-life varied from 3 h to 4 h.",Pharmacokinetics and metabolism of torasemide in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370063/),h,4,31219,DB00214,Torasemide
,3370063,systemic clearance,Only a quarter of the low systemic clearance of torasemide (41 ml/min) was accounted for by renal clearance.,Pharmacokinetics and metabolism of torasemide in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370063/),[ml] / [min],41,31220,DB00214,Torasemide
,3370063,distribution volume,The distribution volume of 15.5 l was in the order of the extracellular fluid volume.,Pharmacokinetics and metabolism of torasemide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370063/),l,15.5,31221,DB00214,Torasemide
,1712713,tau,tau averaged 6 hours and was independent of CLcr.,The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712713/),h,6,37324,DB00214,Torasemide
,1712713,half-life (t1/2),"The mean half-life (t1/2) of torasemide was approximately 5 hours and was independent of renal function, since renal clearance accounted for only around 25% of total body clearance.",The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712713/),h,5,37325,DB00214,Torasemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,94.3,41055,DB00214,Torasemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,92.9,41056,DB00214,Torasemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,95.6,41057,DB00214,Torasemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,77.5,41058,DB00214,Torasemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,66.6,41059,DB00214,Torasemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,76.5,41060,DB00214,Torasemide
,29770976,peak concentration (Cmax ),"Pharmacokinetic analysis identified a peak concentration (Cmax ) of 10.14 µg/mL (range, 6.79-14.69 µg/mL) and elimination half-life (T1/2 ) 9.2 hours (range, 8.4-10.4 hours).",Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29770976/),[μg] / [ml],10.14,46678,DB00214,Torasemide
,29770976,elimination half-life (T1/2 ),"Pharmacokinetic analysis identified a peak concentration (Cmax ) of 10.14 µg/mL (range, 6.79-14.69 µg/mL) and elimination half-life (T1/2 ) 9.2 hours (range, 8.4-10.4 hours).",Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29770976/),h,9.2,46679,DB00214,Torasemide
,29770976,area under the plasma drug concentration over time curve (AUC),"The area under the plasma drug concentration over time curve (AUC) was 80.7 µg × h/mL (range, 56.5-117.2 µg × h/mL).",Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29770976/),[h·μg] / [ml],80.7,46680,DB00214,Torasemide
,8033494,maximum urinary sodium excretion rate,"The maximum urinary sodium excretion rate attained was about 0.6 mEq/min, which is about 20% of that in healthy subjects, indicating diuretic resistance in these patients.",The pharmacodynamics of torsemide in patients with congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033494/),[meq] / [min],0.6,47564,DB00214,Torasemide
,15295798,AUC,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[min·μg] / [ml],1880,60036,DB00214,Torasemide
,15295798,AUC,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[min·μg] / [ml],4080,60037,DB00214,Torasemide
,15295798,AUC,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[min·μg] / [ml],2290,60038,DB00214,Torasemide
,15295798,terminal half-life,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),min,188,60039,DB00214,Torasemide
,15295798,terminal half-life,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),min,277,60040,DB00214,Torasemide
,15295798,terminal half-life,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),min,139,60041,DB00214,Torasemide
,15295798,MRT,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),min,154,60042,DB00214,Torasemide
,15295798,MRT,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),min,323,60043,DB00214,Torasemide
,15295798,MRT,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),min,155,60044,DB00214,Torasemide
,15295798,CL,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [kg·min],1.06,60045,DB00214,Torasemide
,15295798,CL,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [kg·min],0.491,60046,DB00214,Torasemide
,15295798,CL,"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [kg·min],0.943,60047,DB00214,Torasemide
,15295798,CL(NR),"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [kg·min],0,60048,DB00214,Torasemide
,15295798,CL(NR),"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [kg·min],0.430,60049,DB00214,Torasemide
,15295798,CL(NR),"This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [kg·min],0.874,60050,DB00214,Torasemide
,15295798,"disappearance clearance, CL(int)","This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [mg·min],0,60051,DB00214,Torasemide
,15295798,"disappearance clearance, CL(int)","This was proven by the following parameters; the AUC (1880, 4080, and 2290 microg x min/mL for control rats and rats with PCM and PCMC, respectively), terminal half-life (188, 277, and 139 min), MRT (154, 323, and 155 min), CL (1.06, 0.491, and 0.943 mL/min/kg), CL(NR) (0.992, 0.430, and 0.874 mL/min/kg), and in vitro intrinsic torasemide disappearance clearance, CL(int) (0.102, 0.0842, and 0.0997 mL/min/mg protein).",Effects of cysteine on the pharmacokinetics of intravenous torasemide in rats with protein-calorie malnutrition. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295798/),[ml] / [mg·min],0.0997,60052,DB00214,Torasemide
,16969365,total oral clearance,"Torsemide total oral clearance was linearly associated with the number of CYP2C9(*)3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the carboxylation clearance.",Genetic variation at the CYP2C locus and its association with torsemide biotransformation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969365/),[ml] / [min],59,79405,DB00214,Torasemide
,16969365,total oral clearance,"Torsemide total oral clearance was linearly associated with the number of CYP2C9(*)3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the carboxylation clearance.",Genetic variation at the CYP2C locus and its association with torsemide biotransformation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969365/),[ml] / [min],40,79406,DB00214,Torasemide
,16969365,total oral clearance,"Torsemide total oral clearance was linearly associated with the number of CYP2C9(*)3 alleles (geometric mean: 59, 40 and 20 ml/min in carriers of no, one and two alleles) and so were the methyl- and ring-hydroxylation but not the carboxylation clearance.",Genetic variation at the CYP2C locus and its association with torsemide biotransformation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16969365/),[ml] / [min],20,79407,DB00214,Torasemide
,7781259,time to reach maximum concentration [tmax],"Torsemide (time to reach maximum concentration [tmax], 1.1 +/- 0.9 hour) was more rapidly absorbed than furosemide (tmax, 2.4 +/- 2.5 hours), the absorption of which was delayed compared with that in healthy volunteers.","Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781259/),h,1.1,100350,DB00214,Torasemide
,7781259,tmax,"Torsemide (time to reach maximum concentration [tmax], 1.1 +/- 0.9 hour) was more rapidly absorbed than furosemide (tmax, 2.4 +/- 2.5 hours), the absorption of which was delayed compared with that in healthy volunteers.","Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781259/),h,2.4,100351,DB00214,Torasemide
,11718311,extraction recoveries,"The mean extraction recoveries are 78% for M5 and 60% for torasemide, and the limits of quantitation are 1 and 8 ng/mL, respectively.",Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography-electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11718311/),%,78,114808,DB00214,Torasemide
,11718311,extraction recoveries,"The mean extraction recoveries are 78% for M5 and 60% for torasemide, and the limits of quantitation are 1 and 8 ng/mL, respectively.",Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography-electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11718311/),%,60,114809,DB00214,Torasemide
,15841492,absolute oral bioavailability (F),"Hence, the extent of absolute oral bioavailability (F) was also independent of oral doses; the values were 95.6, 98.8, and 97.3% for oral doses of 1, 5, and 10 mg/kg, respectively.",Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841492/),%,95.6,116732,DB00214,Torasemide
,15841492,absolute oral bioavailability (F),"Hence, the extent of absolute oral bioavailability (F) was also independent of oral doses; the values were 95.6, 98.8, and 97.3% for oral doses of 1, 5, and 10 mg/kg, respectively.",Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841492/),%,98.8,116733,DB00214,Torasemide
,15841492,absolute oral bioavailability (F),"Hence, the extent of absolute oral bioavailability (F) was also independent of oral doses; the values were 95.6, 98.8, and 97.3% for oral doses of 1, 5, and 10 mg/kg, respectively.",Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841492/),%,97.3,116734,DB00214,Torasemide
,15841492,hepatic extraction ratio,"After intravenous administration, the total body clearances of torasemide were extensively slower than the reported cardiac output in rats and hepatic extraction ratio was only 3-4% suggesting almost negligible first-pass effects of torasemide in the heart, lung, and liver in rats.",Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841492/),%,3-4,116735,DB00214,Torasemide
,15841492,Protein binding,Protein binding of torasemide to fresh rat plasma was 93.9 +/- 1.53% using an equilibrium dialysis technique.,Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841492/),%,93.9,116736,DB00214,Torasemide
,14713362,Total body,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],4.53,117189,DB00214,Torasemide
,14713362,Total body,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],5.72,117190,DB00214,Torasemide
,14713362,Total body,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],10.0,117191,DB00214,Torasemide
,14713362,Total body,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],4.45,117192,DB00214,Torasemide
,14713362,renal clearance,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],1.44,117193,DB00214,Torasemide
,14713362,renal clearance,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],1.87,117194,DB00214,Torasemide
,14713362,renal clearance,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],6.78,117195,DB00214,Torasemide
,14713362,renal clearance,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),[ml] / [kg·min],1.72,117196,DB00214,Torasemide
,14713362,total amount of unchanged torasemide excreted in,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),μg,694,117197,DB00214,Torasemide
,14713362,total amount of unchanged torasemide excreted in,"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),μg,1310,117198,DB00214,Torasemide
,14713362,A(e 0-8 h),"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),μg,694,117199,DB00214,Torasemide
,14713362,A(e 0-8 h),"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),μg,780,117200,DB00214,Torasemide
,14713362,A(e 0-8 h),"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),μg,1310,117201,DB00214,Torasemide
,14713362,A(e 0-8 h),"Total body (4.53, 5.72, 10.0 and 4.45 mL min(-1) kg(-1) for treatments 1-4, respectively) and renal clearance (1.44, 1.87, 6.78 and 1.72 mL min(-1) kg(-1)) of torasemide, and total amount of unchanged torasemide excreted in 8-h urine (A(e 0-8 h): 694, 780, 1310 and 1040 microg) in treatment 3 were considerably faster and greater compared with treatments 1, 2 and 4.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),μg,1040,117202,DB00214,Torasemide
,14713362,urine output,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),ml,101,117203,DB00214,Torasemide
,14713362,urine output,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),ml,185,117204,DB00214,Torasemide
,14713362,urine output,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),ml,808,117205,DB00214,Torasemide
,14713362,urine output,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),ml,589,117206,DB00214,Torasemide
,14713362,sodium excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,10.1,117207,DB00214,Torasemide
,14713362,sodium excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,20.6,117208,DB00214,Torasemide
,14713362,sodium excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,89.2,117209,DB00214,Torasemide
,14713362,sodium excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,29.9,117210,DB00214,Torasemide
,14713362,chloride excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,14.5,117211,DB00214,Torasemide
,14713362,chloride excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,27.9,117212,DB00214,Torasemide
,14713362,chloride excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,94.0,117213,DB00214,Torasemide
,14713362,chloride excretion,"For example, the mean 8-h urine output was 101, 185, 808 and 589 mL for treatments 1-4, respectively, and the corresponding values for sodium excretion were 10.1, 20.6, 89.2 and 29.9 mmol, and for chloride excretion were 14.5, 27.9, 94.0 and 37.2 mmol.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous torasemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14713362/),mM,37.2,117214,DB00214,Torasemide
,29403968,flow rate,"The chromatography was performed on a Gl Sciences Inertsil ODS-3 column (100 mm×2.1 mm i.d., 5.0 µm) within 5 min, using methanol with 10 mM ammonium formate (60:40, v/v) as mobile phase at a flow rate of 0.2 mL/min.",Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),[ml] / [min],0.2,122229,DB00214,Torasemide
,29403968,m/z,The targeted compound was detected in negative ionization at m/z 347.00 for torasemide and 269.00 for IS.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),,347.00,122230,DB00214,Torasemide
,29403968,m/z,The targeted compound was detected in negative ionization at m/z 347.00 for torasemide and 269.00 for IS.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),,269.00,122231,DB00214,Torasemide
,29403968,extracted recovery efficiency,The extracted recovery efficiency was from 84.20% to 86.47% at three concentration levels.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),%,84.20,122232,DB00214,Torasemide
,29403968,extracted recovery efficiency,The extracted recovery efficiency was from 84.20% to 86.47% at three concentration levels.,Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403968/),%,86.47,122233,DB00214,Torasemide
,3370058,plasma elimination half-life,In accordance with the pharmacodynamic characteristics plasma elimination half-life of torasemide was about 1.5 h in the rat and bioavailability was nearly complete.,Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370058/),h,1.5,135635,DB00214,Torasemide
,3370061,duration of action,"Thus, the duration of action averaged 3-4 h and only moderate rebound effects were detected.",Dose-response curve for torasemide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370061/),h,3-4,137637,DB00214,Torasemide
,15248190,urine output,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),ml,235,144796,DB00214,Torasemide
,15248190,urine output,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),ml,534,144797,DB00214,Torasemide
,15248190,urine output,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),ml,808,144798,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),mM,24.2,144799,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),mM,80.1,144800,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),mM,89.2,144801,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),mM,27.1,144802,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),mM,94.0,144803,DB00214,Torasemide
,15248190,total,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),μg,1210,144804,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),μg,1210,144805,DB00214,Torasemide
,15248190,urinary excretion,"However, the 8 h urine output (235, 534 and 808 ml) and 8 h urinary excretion of sodium (24.2, 80.1 and 89.2 mmol) and chloride (27.1, 89.2 and 94.0 mmol) were significantly greater in treatments II and III than those in treatment I, although the total 8 h urinary excretion of unchanged torasemide (1210, 1210 and 1310 microg) were not significantly different among the three treatments.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of torasemide in rabbits. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248190/),μg,1310,144806,DB00214,Torasemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),[μg] / [ml],11.0,146140,DB00214,Torasemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),[μg] / [ml],13.9,146141,DB00214,Torasemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),<,3.1,146142,DB00214,Torasemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),[μg] / [ml],3.9,146143,DB00214,Torasemide
,9674715,time to maximum concentration,The time to maximum concentration decreased from 1.40+/-.82 h to 0.81+/-0.36 with torsemide (P <0.01).,The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),h,1.40,146144,DB00214,Torasemide
,9674715,time to maximum concentration,The time to maximum concentration decreased from 1.40+/-.82 h to 0.81+/-0.36 with torsemide (P <0.01).,The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),,0.81,146145,DB00214,Torasemide
,15592327,total oral clearance,"Median torsemide total oral clearance values were 3.4, 2.2, and 1.2 L/h in carriers of the CYP2C9 genotypes *1/*1 , *1/*3 , and *3/*3 , respectively, but there was no significant difference related to CYP2C9*2 .",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],3.4,160819,DB00214,Torasemide
,15592327,total oral clearance,"Median torsemide total oral clearance values were 3.4, 2.2, and 1.2 L/h in carriers of the CYP2C9 genotypes *1/*1 , *1/*3 , and *3/*3 , respectively, but there was no significant difference related to CYP2C9*2 .",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],2.2,160820,DB00214,Torasemide
,15592327,total oral clearance,"Median torsemide total oral clearance values were 3.4, 2.2, and 1.2 L/h in carriers of the CYP2C9 genotypes *1/*1 , *1/*3 , and *3/*3 , respectively, but there was no significant difference related to CYP2C9*2 .",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],1.2,160821,DB00214,Torasemide
,15592327,formation clearance,"Values for metabolite formation clearance via metabolites M1 and M5 were 1.4, 1.7, 1.4, 1.0, 0.77, and 0.18 L/h in carriers of genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively (P < .001).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],1.4,160822,DB00214,Torasemide
,15592327,formation clearance,"Values for metabolite formation clearance via metabolites M1 and M5 were 1.4, 1.7, 1.4, 1.0, 0.77, and 0.18 L/h in carriers of genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively (P < .001).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],1.7,160823,DB00214,Torasemide
,15592327,formation clearance,"Values for metabolite formation clearance via metabolites M1 and M5 were 1.4, 1.7, 1.4, 1.0, 0.77, and 0.18 L/h in carriers of genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively (P < .001).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],1.0,160824,DB00214,Torasemide
,15592327,formation clearance,"Values for metabolite formation clearance via metabolites M1 and M5 were 1.4, 1.7, 1.4, 1.0, 0.77, and 0.18 L/h in carriers of genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively (P < .001).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],0.77,160825,DB00214,Torasemide
,15592327,formation clearance,"Values for metabolite formation clearance via metabolites M1 and M5 were 1.4, 1.7, 1.4, 1.0, 0.77, and 0.18 L/h in carriers of genotypes *1/*1 , *1/*2 , *2/*2 , *1/*3 , *2/*3 , and *3/*3 , respectively (P < .001).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),[l] / [h],0.18,160826,DB00214,Torasemide
,15592327,24-hour,"From 0 to 8 hours after torsemide administration, Na + , K + , and Cl - elimination was higher in carriers of CYP2C9*3 alleles than in carriers of the homozygous wild-type genotype, and 24-hour uric acid elimination values in urine were 451, 350, and 249 mg in carriers of 0, 1, and 2 CYP2C9*3 alleles, respectively (P = .003).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),mg,451,160827,DB00214,Torasemide
,15592327,24-hour,"From 0 to 8 hours after torsemide administration, Na + , K + , and Cl - elimination was higher in carriers of CYP2C9*3 alleles than in carriers of the homozygous wild-type genotype, and 24-hour uric acid elimination values in urine were 451, 350, and 249 mg in carriers of 0, 1, and 2 CYP2C9*3 alleles, respectively (P = .003).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),mg,350,160828,DB00214,Torasemide
,15592327,24-hour,"From 0 to 8 hours after torsemide administration, Na + , K + , and Cl - elimination was higher in carriers of CYP2C9*3 alleles than in carriers of the homozygous wild-type genotype, and 24-hour uric acid elimination values in urine were 451, 350, and 249 mg in carriers of 0, 1, and 2 CYP2C9*3 alleles, respectively (P = .003).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),mg,249,160829,DB00214,Torasemide
,15592327,elimination,"From 0 to 8 hours after torsemide administration, Na + , K + , and Cl - elimination was higher in carriers of CYP2C9*3 alleles than in carriers of the homozygous wild-type genotype, and 24-hour uric acid elimination values in urine were 451, 350, and 249 mg in carriers of 0, 1, and 2 CYP2C9*3 alleles, respectively (P = .003).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),mg,451,160830,DB00214,Torasemide
,15592327,elimination,"From 0 to 8 hours after torsemide administration, Na + , K + , and Cl - elimination was higher in carriers of CYP2C9*3 alleles than in carriers of the homozygous wild-type genotype, and 24-hour uric acid elimination values in urine were 451, 350, and 249 mg in carriers of 0, 1, and 2 CYP2C9*3 alleles, respectively (P = .003).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),mg,350,160831,DB00214,Torasemide
,15592327,elimination,"From 0 to 8 hours after torsemide administration, Na + , K + , and Cl - elimination was higher in carriers of CYP2C9*3 alleles than in carriers of the homozygous wild-type genotype, and 24-hour uric acid elimination values in urine were 451, 350, and 249 mg in carriers of 0, 1, and 2 CYP2C9*3 alleles, respectively (P = .003).",CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15592327/),mg,249,160832,DB00214,Torasemide
,8330470,bioavailability,"Torsemide was rapidly absorbed with a bioavailability of 96.3% (confidence interval, 84% to 109%).","Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8330470/),%,96.3,173888,DB00214,Torasemide
,9474471,bioavailablity,"It is well absorbed and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema.",Clinical pharmacokinetics and pharmacodynamics of torasemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),%,80,183581,DB00214,Torasemide
,9474471,volume of distribution,The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[l] / [kg],0.2,183582,DB00214,Torasemide
,9474471,volume of distribution,The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[l] / [kg],0.11 to 0.18,183583,DB00214,Torasemide
,9474471,maximum natriuretic effect,The maximum natriuretic effect of all loop diuretics amounts to about 3 mmol Na+/min.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[mM·na+] / [min],3,183584,DB00214,Torasemide
,3608350,total clearance,"Although total clearance was the same with all doses (about 0.45 ml/min/kg), renal clearance and the fraction of unchanged drug appearing in the urine decreased with higher doses raising the question of saturable renal secretion.","Clinical pharmacology of torasemide, a new loop diuretic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608350/),[ml] / [kg·min],0.45,188327,DB00214,Torasemide
greater,7118326,bioavailability,"A new diuretic drug, torasemide, after oral or i. v. administration of 20 mg to six normal volunteers showed good bioavailability (greater than 91%).",Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7118326/),%,91,195486,DB00214,Torasemide
,7118326,biologic half-life,Its biologic half-life is about 2.5 h with a distribution volume of 180 ml/kg and a body clearance of 0.8 ml/min kg.,Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7118326/),h,2.5,195487,DB00214,Torasemide
,7118326,distribution volume,Its biologic half-life is about 2.5 h with a distribution volume of 180 ml/kg and a body clearance of 0.8 ml/min kg.,Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7118326/),[ml] / [kg],180,195488,DB00214,Torasemide
,7118326,body clearance,Its biologic half-life is about 2.5 h with a distribution volume of 180 ml/kg and a body clearance of 0.8 ml/min kg.,Pharmacokinetic study of torasemide in humans: an overview of its diuretic effect. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7118326/),[ml] / [kg·min],0.8,195489,DB00214,Torasemide
,15890479,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) of torasemide was significantly greater in rats pretreated with SKF 525-A (a non-specific CYP isozyme inhibitor in rats) than that in control rats (3570 versus 1350 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],3570,223408,DB00214,Torasemide
,15890479,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) of torasemide was significantly greater in rats pretreated with SKF 525-A (a non-specific CYP isozyme inhibitor in rats) than that in control rats (3570 versus 1350 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1350,223409,DB00214,Torasemide
,15890479,AUC,"However, in rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the AUC was significantly smaller than that in control rats (1290 versus 1590 microg min/ml).",Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1290,223410,DB00214,Torasemide
,15890479,AUC,"However, in rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the AUC was significantly smaller than that in control rats (1290 versus 1590 microg min/ml).",Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1590,223411,DB00214,Torasemide
,15890479,AUC,It has been reported from our laboratories that in rats pretreated with sulfaphenazole (a main inhibitor of CYP2C11 in rats) the AUC was significantly greater than that in control rats (2970 versus 1610 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],2970,223412,DB00214,Torasemide
,15890479,AUC,It has been reported from our laboratories that in rats pretreated with sulfaphenazole (a main inhibitor of CYP2C11 in rats) the AUC was significantly greater than that in control rats (2970 versus 1610 microg min/ml).,Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15890479/),[min·μg] / [ml],1610,223413,DB00214,Torasemide
,21623723,bioavailability,It has higher bioavailability (&gt;80%) and a longer elimination half-life (3 to 4 hours) than furosemide.,[Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623723/),%,80,234510,DB00214,Torasemide
,21623723,elimination half-life,It has higher bioavailability (&gt;80%) and a longer elimination half-life (3 to 4 hours) than furosemide.,[Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623723/),h,3 to 4,234511,DB00214,Torasemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],199,240219,DB00214,Torasemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],357,240220,DB00214,Torasemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],213,240221,DB00214,Torasemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],398,240222,DB00214,Torasemide
,19934028,body-weight-normalized area under the concentration-time curve,"Torasemide elimination was significantly reduced in women compared with men (eg, body-weight-normalized area under the concentration-time curve: 42.1 +/- 20.4 vs 30.9 +/- 10.3 kg.h/L; P < .001).",Gender is an important determinant of the disposition of the loop diuretic torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19934028/),[h·kg] / [l],42.1,242703,DB00214,Torasemide
,19934028,body-weight-normalized area under the concentration-time curve,"Torasemide elimination was significantly reduced in women compared with men (eg, body-weight-normalized area under the concentration-time curve: 42.1 +/- 20.4 vs 30.9 +/- 10.3 kg.h/L; P < .001).",Gender is an important determinant of the disposition of the loop diuretic torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19934028/),[h·kg] / [l],30.9,242704,DB00214,Torasemide
,19934028,K(m),"Using cell lines expressing OATP1B1, the authors identified torasemide as OATP1B1 substrate (K(m) = 6.2 microM) with a significant reduction of uptake by the 521C-variant.",Gender is an important determinant of the disposition of the loop diuretic torasemide. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19934028/),μM,6.2,242705,DB00214,Torasemide
,2076715,t1/2,"Torasemide had a t1/2 of about 4h which was independent of kidney function, as the nonrenal clearance of torasemide was 3-times greater than its renal clearance.",Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2076715/),h,4,248118,DB00214,Torasemide
,18399713,"dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],375.5,250691,DB00214,Torasemide
,18399713,"dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],548.5,250692,DB00214,Torasemide
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],352.3,250693,DB00214,Torasemide
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],487.6,250694,DB00214,Torasemide
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],359.5,250695,DB00214,Torasemide
,18399713,"AUC(24,ss)/D","Factorial ANOVA revealed an independent impact of the CYP2C9 genotype (dose-normalized area under the plasma concentration-time curve during the 24-hour dosing interval at steady state [AUC(24,ss)/D]: *1/*1 375.5+/-151.4 microg x h/L/mg vs *1/*3 548.5+/-271.6 microg x h/L/mg, p=0.001), the SLCO1B1 genotype (AUC(24,ss)/D: TT 352.3+/-114 microg x h/L/mg vs TC 487.6+/-218.4 microg x h/L/mg, p<0.05) and gender (AUC(24,ss)/D: males 359.5+/-72.2 microg x h/L/mg vs females 547.3+/-284 microg x h/L/mg, p<0.01) on disposition of torasemide.","Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18399713/),[h·μg] / [l·mg],547.3,250696,DB00214,Torasemide
,3285830,serum elimination half-life,The serum elimination half-life of torasemide was longer (4.8 h) than that of furosemide (2.2 h) in these patients and also longer than that in healthy volunteers (3 h).,Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285830/),h,4.8,254124,DB00214,Torasemide
,3285830,serum elimination half-life,The serum elimination half-life of torasemide was longer (4.8 h) than that of furosemide (2.2 h) in these patients and also longer than that in healthy volunteers (3 h).,Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285830/),h,2.2,254125,DB00214,Torasemide
,3285830,serum elimination half-life,The serum elimination half-life of torasemide was longer (4.8 h) than that of furosemide (2.2 h) in these patients and also longer than that in healthy volunteers (3 h).,Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285830/),h,3,254126,DB00214,Torasemide
,12516076,AUC,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[μg] / [min·ml],301,258455,DB00214,Torasemide
,12516076,AUC,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[μg] / [min·ml],2680,258456,DB00214,Torasemide
,12516076,Cl(r),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],4.81,258457,DB00214,Torasemide
,12516076,Cl(r),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],0.386,258458,DB00214,Torasemide
,12516076,Cl(nr),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],28.3,258459,DB00214,Torasemide
,12516076,Cl(nr),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],3.33,258460,DB00214,Torasemide
,12516076,terminal half-life,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,18.3,258461,DB00214,Torasemide
,12516076,terminal half-life,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,73.5,258462,DB00214,Torasemide
,12516076,mean residence time,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,6.97,258463,DB00214,Torasemide
,12516076,mean residence time,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,61.8,258464,DB00214,Torasemide
,12516076,Cl,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],33.2,258465,DB00214,Torasemide
,12516076,Cl,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],3.74,258466,DB00214,Torasemide
,12516076,urinary excretion,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),μg,446,258467,DB00214,Torasemide
,12516076,urinary excretion,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),μg,323,258468,DB00214,Torasemide
,27230410,"maximum inhibition of loss of response, Imax","Estimated maximum inhibition of loss of response, Imax , was 0.984 showing that torasemide is an efficacious diuretic able to suppress almost total water reabsorption.",A pharmacokinetic/pharmacodynamic model capturing the time course of torasemide-induced diuresis in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230410/),,0.984,262845,DB00214,Torasemide
,27230410,TERU50,"A TERU50, value producing half of Imax , of 1.45 μg/kg/h was estimated from the model.",A pharmacokinetic/pharmacodynamic model capturing the time course of torasemide-induced diuresis in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27230410/),[μg] / [h·kg],1.45,262846,DB00214,Torasemide
,3370062,plasma elimination half-life,"The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,2.2,273096,DB00214,Torasemide
,3370062,plasma elimination half-life,"The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,2.8,273097,DB00214,Torasemide
,3370062,bioavailability,"The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),%,91,273098,DB00214,Torasemide
,3370062,plasma elimination half-life,"For furosemide, a plasma elimination half-life of 0.6 h for i.v. and 0.8 h for oral application was found.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,0.6,273099,DB00214,Torasemide
,3370062,plasma elimination half-life,"For furosemide, a plasma elimination half-life of 0.6 h for i.v. and 0.8 h for oral application was found.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,0.8,273100,DB00214,Torasemide
,3370062,bioavailability,"The bioavailability was 40%, and about 62% of the drug was excreted via the kidney.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),%,40,273101,DB00214,Torasemide
,3370062,bioavailability,"The bioavailability was 40%, and about 62% of the drug was excreted via the kidney.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),%,62,273102,DB00214,Torasemide
